Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

Civil Society Organisations oppose Gilead's patent applications for lenacapavir in India: Our Bureau, New Delhi Tuesday, September 17, 2024, 15:40 Hrs [IST] Civil society organisa ...

The DMC recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants. The company said the data from the PURPOSE 1 and PURPOSE 2 trials will ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...

Civil society organisations opposing the patent applications of US-based pharma major Gilead Sciences for the HIV drug lenacapavir have said that generic competition is needed to make the long acting ...